迟发性扩张型心肌病与肌联蛋白变异的关联
研究纳入7个国际中心1990至2020年就诊的184例60岁以上迟发性扩张型心肌病患者,36%携带致病或可能致病变异,其中肌联蛋白截断变异占69%。中位随访42个月,13%死亡,基因阳性者死亡率高于阴性者。
要点
- 迟发性扩张型心肌病患者中致病或可能致病变异携带率高达36%。
- 肌联蛋白截断变异是最常见变异类型,占基因阳性患者的69%。
- 基因阳性患者全因死亡率高于基因阴性患者,支持老年患者也应接受基因检测。
核心结论
- 迟发性扩张型心肌病可能是一个以高遗传变异负荷为特征的独特亚组,主要由肌联蛋白截断变异驱动。
- 基因检测阳性的迟发性扩张型心肌病患者全因死亡率高于基因阴性患者。
- 研究结果支持在老年患者中扩大基因检测的应用。
研究设计与样本
- 研究为多中心队列研究,纳入7个国际三级转诊中心1990年3月至2020年8月接受基因检测的迟发性扩张型心肌病患者。
- 共纳入184例60岁以上患者,女性103例(56%),平均(标准差)年龄67(6)岁,平均(标准差)左心室射血分数32%(10%)。
- 阳性基因型定义为存在致病或可能致病(P/LP)变异,研究结局为全因死亡。
主要发现
- 肌联蛋白截断变异最常见,占全部人群的25%(46例),占所有基因阳性患者的69%(46例)。
- 中位(四分位距)随访42(10-115)个月期间,23例患者(13%)死亡。
- 死亡患者中17例(25%)为致病或可能致病变异携带者,6例(5.1%)为基因阴性。
临床怎么用
- 对60岁以上迟发性扩张型心肌病患者应考虑进行基因检测,尤其关注肌联蛋白截断变异。
- 基因检测结果阳性可提示更高的死亡风险,有助于风险分层管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Dilated cardiomyopathy (DCM) is frequently caused by genetic factors. Studies identifying deleterious rare variants have predominantly focused on early-onset cases, and little is known about the genetic underpinnings of the growing numbers of patients with DCM who are diagnosed when they are older than 60 years (ie, late-onset DCM). OBJECTIVE: To investigate the prevalence, type, and prognostic impact of disease-associated rare variants in patients with late-onset DCM. DESIGN, SETTING, AND PARTICIPANTS: A population of patients with late-onset DCM who had undergone genetic testing in 7 international tertiary referral centers worldwide were enrolled from March 1990 to August 2020. A positive genotype was defined as the presence of pathogenic or likely pathogenic (P/LP) variants. MAIN OUTCOMES AND MEASURES: The study outcome was all-cause mortality. RESULTS: A total of 184 patients older than 60 years (103 female [56%]; mean [SD] age, 67 [6] years; mean [SD] left ventricular ejection fraction, 32% [10%]) were studied. Sixty-six patients (36%) were carriers of a P/LP variant. Titin-truncating variants were the most prevalent (present in 46 [25%] of the total population and accounting for 46 [69%] of all genotype-positive patients). During a median (interquartile range) follow-up of 42 (10-115) months, 23 patients (13%) died; 17 (25%) of these were carriers of P/LP variants, while 6 patients (5.1%) were genotype-negative. CONCLUSIONS AND RELEVANCE: Late-onset DCM might represent a distinct subgroup characterized by and a high genetic variation burden, largely due to titin-truncating variants. Patients with a positive genetic test had higher mortality than genotype-negative patients. These findings support the extended use of genetic testing also in older patients.
引用
- Cannatà A, Merlo M, Dal Ferro M, et al. Association of Titin Variations With Late-Onset Dilated Cardiomyopathy. JAMA Cardiol. 2022. PMID: 35138330. doi:10.1001/jamacardio.2021.5890
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。